11 Supported by research
One in five women will be diagnosed with Alzheimer's disease.
"Uh, one in five women will be diagnosed with Alzheimer's." (said at 0:15:01)
Large prospective cohort data establish that the estimated remaining lifetime risk of developing Alzheimer's disease or dementia for a woman is approximately 1 in 5 (around 20%), compared to roughly 1 in 10 for men. In the Framingham Heart Study, which prospectively tracked participants and accounted for competing mortality risks, the estimated lifetime risk of dementia/Alzheimer's disease was 1 in 5 for women starting from midlife.
Two-thirds of the people diagnosed with Alzheimer's disease are women.
"Two-thirds of the people diagnosed with Alzheimer's are women." (said at 0:15:01)
Large-scale epidemiological studies and comprehensive reviews consistently confirm that women account for approximately two-thirds (roughly 60% to 67%) of all diagnosed Alzheimer's disease cases. This difference is driven both by women's longer average life expectancy and by distinct sex-specific biological and hormonal risk factors.
Stroboscopic 40 Hz flashing light can cause nausea and headaches in users.
"Most use what's called stroboscopic light, and that's the type of light that flashes. Then you can see the flashing, and that can cause nausea. It can cause headaches." (said at 0:18:41)
Visible stroboscopic light flickering (including at 40 Hz gamma frequencies) is known to induce visual discomfort, eyestrain, headaches, and nausea in susceptible individuals, particularly with prolonged exposure or higher luminance intensities. Because stroboscopic 40 Hz flashing can be strenuous and cause compliance issues due to these side effects, researchers have investigated alternative methods such as invisible spectral flicker (ISF) to improve tolerability while maintaining neural entrainment.
Exercise enhances production of brain-derived neurotrophic factor (BDNF), leading to neurogenesis, synaptogenesis, reduced inflammation, and improved insulin function.
"Well, we get the idea that exercise enhances the production in the brain of BDNF. It's a trophic hormone, leads to neurogenesis, synaptogenesis, all the things, reduces inflammation, improves insulin functionality, all of that." (said at 0:26:55)
Exercise increases the synthesis and circulating levels of brain-derived neurotrophic factor (BDNF), a neurotrophin that plays a key role in adult hippocampal neurogenesis, synaptogenesis, and synaptic plasticity. Broad scientific literature and reviews demonstrate that exercise-induced BDNF elevation, along with parallel metabolic and neuroimmune pathways, reduces neuroinflammation and improves insulin sensitivity and glucose homeostasis.
- supports: The Neuroprotective Effects of Exercise on Cognitive Decline: A Preventive Approach to Alz… (Cureus 2020) · cited 35x in the literature
"Others suggest that exercise causes an increase in angiogenesis, neurogenesis, and synaptogenesis mainly due to an increase in blood flow, brain-derived neurotrophic factor (BDNF), insulin-like growth factor 1 (IGF-1), hormones, and second messengers." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Possible Neuroprotective Mechanisms of Physical Exercise in Neurodegeneration. (International journal of molecular sciences 2020) · cited 326x in the literature
"PE is beneficial for people suffering from neuro-degenerative diseases because it improves the production of neurotrophic factors, neurotransmitters, and hormones. PE promotes neuronal survival and neuroplasticity and also optimizes neuroendocrine and physiological responses to psychosocial and physical stress. PE sensitizes the parasympathetic nervous system ( PNS ), Autonomic Nervous System (ANS) and central nervous system (CNS) by promoting many processes such as synaptic plasticity, neurogenesis, angiogenesis, and autophagy. Overall, it carries out many protective and preventive activities such as improvements in memory, cognition, sleep and mood; growth of new blood vessels in nervous system; and the reduction of stress, anxiety, neuro-inflammation, and insulin resistance." (abstract, results, passage verified)
pubmedfull study (doi)
Adequate sleep promotes BDNF production, neurogenesis, and synaptogenesis while reducing inflammation and improving insulin sensitivity in the brain.
"We get the idea that exercise enhances the production in the brain of BDNF. It's a trophic hormone, leads to neurogenesis, synaptogenesis, all the things, reduces inflammation, improves insulin functionality, all of that. Sleep does the same thing." (said at 0:26:55)
Adequate physiological sleep supports brain health by preserving brain-derived neurotrophic factor (BDNF) levels, facilitating hippocampal adult neurogenesis and synaptic plasticity, and constraining neuroinflammation. Conversely, sleep disruption and deprivation are well-documented across preclinical and clinical literature to decrease BDNF expression, impair neurogenesis and synaptic remodeling, and trigger neuroinflammatory signaling pathways.
Estradiol specifically is critical for the brain's ability to utilize glucose for energy, and reductions in estradiol during perimenopause and menopause impair brain energy metabolism.
"And glucose is that primary energy source for the brain. But what happens in perimenopause and into menopause, as those estradiol levels drop, it turns out estrogen, estradiol specifically, is really critical for the brain's ability to use glucose for energy. And so when we start to have those declines, and as those declines become more pronounced as we get closer to menopause, those estradiol reductions really impact our brain's ability to have the energy that it needs to function well." (said at 0:31:28)
Preclinical and human neuroimaging studies demonstrate that 17β-estradiol acts as a master regulator of cerebral glucose metabolism and mitochondrial bioenergetics. During the perimenopausal and menopausal transitions, dropping estrogen levels are associated with marked declines in the cerebral metabolic rate of glucose (CMRglc) as measured by FDG-PET imaging, as well as reductions in mitochondrial cytochrome oxidase activity, leading to an established regional hypometabolic bioenergetic phenotype.
- supports: Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implicat… (Advanced drug delivery reviews 2008) · cited 155x in the literature
"Overall, E(2) promotes the energetic capacity of brain mitochondria by maximizing aerobic glycolysis (oxidative phosphorylation coupled to pyruvate metabolism)." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and peripher… (PloS one 2017) · cited 186x in the literature
"In animals, estrogenic regulation of cerebral glucose metabolism (CMRglc) falters during perimenopause. This is evident in glucose hypometabolism and decline in mitochondrial efficiency which is sustained thereafter... Both MENO and PERI groups exhibited reduced CMRglc in AD-vulnerable regions which was correlated with decline in mitochondrial COX activity compared to CNT (p's<0.001). A gradient in biomarker abnormalities was most pronounced in MENO, intermediate in PERI, and lowest in CNT (p<0.001)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: A tale of two systems: Lessons learned from female mid-life aging with implications for Al… (Ageing research reviews 2022) · cited 50x in the literature
"The dismantling of the estrogen control of glucose metabolism during mid-life aging is a critical contributor to the shift in fuel systems and emergence of dynamic neuroimmune phenotype." (abstract, results, passage verified)
pubmedfull study (doi)
Approximately 30% of frontotemporal dementia cases are genetic or familial, while 70% of cases are sporadic.
"I know that for, you know, 30%, it can be in genetics, you know, you can see this or within the family, and you can see it through a grandmother, a brother, and, you know, you can see sort of that lineage. And then for, you know, 70% of people with FTD, it's sporadic, meaning it just can happen" (said at 0:39:57)
Published reviews and epidemiological data on frontotemporal dementia (FTD) confirm that approximately 30% to 40% of FTD cases are familial or heritable, while the remaining 60% to 70% are sporadic.
Projections indicate that dementia cases worldwide are expected to triple by the year 2050.
"we're at a time where, you know, they say like 2050 dementia cases are going to triple." (said at 0:41:10)
Global Burden of Disease Study projections published in The Lancet Public Health estimate that the number of people living with dementia worldwide will increase nearly threefold, from approximately 57.4 million in 2019 to 152.8 million by 2050. This projected increase is largely driven by population growth and population ageing.
A 2024 Lancet report found that addressing 14 modifiable risk factors could reduce Alzheimer's and dementia rates by 40% to 50%.
"the Lancet published in 2024 a study indicating that if we paid attention to 14 modifiable factors like reducing alcohol, wearing a helmet when we're bike riding, keeping our blood sugar under control, keeping our blood pressure under control, etc., 14 modifiable factors, that rates of Alzheimer's would not increase, but would be reduced by as much as 40 to 50%." (said at 0:43:15)
The 2024 Lancet Commission report on dementia prevention, intervention, and care updated its life-course model to include 14 modifiable risk factors (including less education, hearing loss, hypertension, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, social isolation, untreated vision loss, and high LDL cholesterol). The report calculated that globally, approximately 45% of dementia cases are attributable to these 14 modifiable risk factors combined (with country-specific population attributable fraction estimates typically ranging between 39% and 60%).
- supports: Population Attributable Fraction of Modifiable Risk Factors for Dementia in Turkey. (Dementia (London, England) 2026) · cited 1x in the literature
"This study aims to estimate the population attributable fractions (PAFs) of 14 modifiable dementia risk factors in Turkey, using the updated 2024 Lancet Commission framework." (abstract, methods, passage verified)
pubmedfull study (doi) - supports: The potential for dementia prevention in Brazil: a population attributable fraction calcul… (Lancet regional health. Americas 2025) · cited 10x in the literature
"The Lancet Commission on dementia prevention, intervention, and care 2024 updated the list of modifiable risk factors to include 14 factors." (abstract, introduction, passage verified)
pubmedfull study (doi) - supports: Broadening dementia risk models: building on the 2024 Lancet Commission report for a more … (EBioMedicine 2025) · cited 31x in the literature
"The 2024 Lancet Commission Report on dementia prevention has identified 14 modifiable risk factors that account for approximately 45% of global dementia cases." (abstract, results, passage verified)
pubmedfull study (doi)
It takes an average of 17 years for research findings to be implemented into clinical medical practice.
"that it takes a really long time, on average 17 years, for things to reach clinical practice once they've been shown in research." (said at 0:48:06)
The statement accurately cites a canonical metric in implementation science. The estimate that it takes an average of 17 years for scientific discoveries to be integrated into routine clinical practice originates from an influential synthesis by Balas and Boren (2000), which modeled the research-to-practice pipeline. Subsequent reviews of time lags in translational research have examined this 17-year figure across multiple clinical domains, noting that while the duration varies widely depending on the intervention type, technology, and study design, a ~17-year average lag is widely documented in the literature.
The annual healthcare cost associated with Alzheimer's disease and dementia is approximately $360 billion.
"because here we are spending $360 billion right now. That's the number that's always quoted." (said at 0:43:30)
According to the Alzheimer's Association's 2024 Facts and Figures report, total payments for healthcare, long-term care, and hospice services for individuals aged 65 and older living with Alzheimer's disease or other dementias in the United States were estimated at $360 billion in 2024.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.